Mustang Bio Secures Funding through Warrant Exercise
Mustang Bio, Inc. is stepping into a significant financial milestone as it announces a recent agreement geared towards the exercise of its existing warrants. This journey in the world of clinical-stage biopharmaceuticals, focused on transforming impactful cell therapies into viable solutions for challenging cancers, is marked by an expected gross revenue of approximately $4 million.
Details of the Warrant Exercise
The exercise encompasses a total of 16,877,638 shares at an exercise price of $0.237 each. Initially issued in May 2024, these warrants have paved the way for a promising venture in raising funds. The total financial boon anticipated from this exercise, before considering fees and expenses, enhances the cash flow for Mustang, equipping it to further its developmental endeavors.
Placement Agent's Role
In this financial operation, H.C. Wainwright & Co. assumes the role of exclusive placement agent, facilitating the offering and ensuring a smooth process moving forward.
New Warrants Issued
To entice immediate cash participation, Mustang will also introduce new unregistered warrants allowing investors to purchase an additional 33,755,276 shares at an exercise price of $0.27 each. These new financial tools will only be active following stockholder approval of the warrant issuance.
Strategic Application of Funds
Mustang's management clearly intends to leverage the net proceeds from this exercise for working capital and general corporate needs, demonstrating a commitment to advancing its business strategy. This decision represents a critical investment in the company’s future, potentially leading to enhanced operational capabilities.
Expected Closing Timeline
The anticipated closure for this offering is projected around late October 2024, contingent on the satisfaction of customary closing conditions. Such a timeline showcases Mustang's eagerness to push forward, rapidly addressing pressing financial necessities essential for growth.
Regulatory Compliance and Future Plans
On the regulatory front, the new warrants will be designated for private placement under Section 4(a)(2) of the Securities Act, ensuring adherence to securities regulations while Mustang plans to file necessary registration statements with the Securities and Exchange Commission.
Mustang Bio's Commitment to Innovation
Founded by Fortress Biotech, Inc., Mustang Bio's vision transcends simple business goals. The company is firmly dedicated to overcoming the formidable challenges presented by difficult-to-treat cancers through innovative therapies, particularly CAR-T therapies. This ambitious journey thrives on strategic partnerships with leading medical institutions, constantly innovating and evolving in the biopharmaceutical landscape.
Contact Information for Further Inquiries
For those interested in learning more about Mustang Bio’s endeavors or the recent warrant exercise, company representatives Jaclyn Jaffe and Nicole McCloskey are available for inquiries. They can be reached at (781) 652-4500 or through email at ir@mustangbio.com.
Frequently Asked Questions
What was announced by Mustang Bio, Inc.?
Mustang Bio announced the exercise of existing warrants expected to generate approximately $4 million in gross proceeds.
What is the purpose of exercising the warrants?
The proceeds will be utilized for working capital and general corporate purposes, enhancing the company's operational capabilities.
Who is the placement agent for this offering?
H.C. Wainwright & Co. is handling the placement of the warrants for Mustang Bio.
What are the terms of the new warrants issued?
The new unregistered warrants will allow the purchase of 33,755,276 shares at an exercise price of $0.27 each, pending stockholder approval.
When is the expected closure for the offering?
The offering is anticipated to close around late October 2024, subject to customary closing conditions.
